Related Experiment Videos

Additive effect of indomethacin and methotrexate on suppression of growth in rats

M P Iqbal1, S A Saeed, S Pertani

  • 1Department of Biochemistry, The Aga Khan University, PO Box 3500, Stadium Road, Karachi, Pakistan. perwaiz.iqbal@aku.edu

Insights

Methotrexate (MTX) and indomethacin combined significantly suppressed growth in young rats, leading to minimal weight gain and reduced organ size. This additive effect may pose risks for patients on long-term therapy.

Area of Science:

  • Pharmacology
  • Toxicology
  • Pediatric Rheumatology

Background:

  • Methotrexate (MTX) and indomethacin are commonly used in treating conditions like juvenile rheumatoid arthritis and acute lymphoblastic leukemia.
  • The potential for combined drug effects on growth, particularly in young individuals, warrants investigation.

Purpose of the Study:

  • To investigate the medium-term effects of concurrent methotrexate and indomethacin administration on the growth of young rats.
  • To assess the impact of these drugs on body weight, organ weights, food consumption, and biochemical markers related to DNA synthesis.

Main Methods:

  • Four groups of Sprague-Dawley male rats were treated with MTX, indomethacin, both, or saline (control) for 10 weeks.
  • Body weight, food/water consumption were monitored regularly.
  • Liver, spleen, and kidney weights were measured, and MTX levels and dihydrofolate reductase activity were analyzed.

Main Results:

  • The group receiving both MTX and indomethacin exhibited minimal body weight increase (17+/-11 g) compared to control and single-drug groups (p=0.001).
  • Significantly reduced liver and spleen weights (p<0.01) and decreased food consumption (p<0.05) were observed in the combined treatment group.
  • Increased MTX accumulation and decreased dihydrofolate reductase activity suggested enhanced inhibition of DNA synthesis.

Conclusions:

  • Methotrexate and indomethacin demonstrate an additive effect in suppressing growth in young rats.
  • Concurrent long-term use of these drugs may pose a risk of short-term growth suppression in pediatric patients.

Related Concept Videos